期刊
LEUKEMIA & LYMPHOMA
卷 62, 期 3, 页码 640-648出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2020.1842397
关键词
Chronic myeloid leukemia; anxiety; depression; tyrosine kinase inhibitor
资金
- National Natural Science Foundation of China [81770161,81970140]
Gender, education level, comorbidities, TKI therapy, and treatment duration are significantly associated with anxiety and/or depression symptoms in chronic myeloid leukemia patients receiving TKI therapy.
Variables associated with self-reported anxiety and depression symptoms were explored in 1169 adults with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI)-therapy. The Self-Rating Anxiety Scale and Self-Rating Depression Scale questionnaires were used to measure anxiety and depression symptoms. Two hundred and fifty-one (22.4%) and 415 (37.1%) respondents reported anxiety and depression, respectively. In multivariate analyses, female sex, lower education level, comorbidities, advanced-line TKI-therapy, and longer TKI-therapy duration were significantly associated with more severe anxiety and/or depression. It is concluded that socio-demographics, comorbidities, advanced-line TKI-therapy, and longer TKI-therapy duration were significantly associated with anxiety and/or depression symptoms in CML patients receiving TKI-therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据